Semaglutide for Weight Loss: Evidence, Expectations & Limits
Quick Answer: In the landmark STEP-1 trial, weekly semaglutide 2.4 mg (Wegovy dosing) produced an average loss of about 15% of body weight over 68 weeks, versus ~2.4% with placebo. Lower diabetes-dose semaglutide produces more modest loss. Around one in three high-dose participants lost 20% or more — and results depend on staying on treatment with diet and activity support.
The Headline Numbers
| Study | Treatment | Average Loss |
|---|---|---|
| STEP-1 (68 weeks) | Semaglutide 2.4 mg weekly | ~14.9% |
| STEP-1 placebo arm | Lifestyle alone | ~2.4% |
| SURMOUNT-5 (head-to-head) | Semaglutide vs tirzepatide | ~14% vs ~20% |
Averages hide spread: many patients exceed them, a minority respond modestly. In practice, dose, adherence, protein intake, and training decide which side of the average you land on.
The Realistic Timeline
- Weeks 1–8: titration; appetite change arrives before major scale change.
- Months 3–6: the strongest loss phase for most patients.
- Months 6–14: continuing loss at a slowing pace toward plateau.
Weight loss on semaglutide is a marathon of consistency, not a sprint — trials ran well over a year.
The Limits, Honestly
- Plateau is built-in: every patient reaches a new equilibrium; that is physiology, not failure.
- Stopping unprepared invites regain: extension studies show substantial regain after abrupt discontinuation — planning the exit is part of the treatment.
- Muscle is at risk: without resistance training and protein, lean mass makes up a meaningful share of what's lost.
- It is not for cosmetic tweaks: the evidence base is for obesity and weight-related disease, under medical care.
FAQs
How much will I lose in the first month? Often modest — titration doses are low; judge the trend at month three, not week four.
Is 15% loss enough to matter medically? Enormously — trials link 10–15% loss to major improvements in blood sugar, blood pressure, liver fat, sleep apnoea and joint symptoms.
Why did my friend lose more on Mounjaro? Tirzepatide's trial averages are higher — see our comparison article; individual response still varies.
Do results differ for Indian patients? Global and regional data show the medication class works across populations; your doctor personalises dosing regardless.
Consult Dr Neha Batra at DermaWorld Skin Clinic, Rajouri Garden, New Delhi 📞 Call: 9911100050 | 💬 WhatsApp Us | 📩 Book via Contact Form Clinic: Q-4, Rajouri Garden, New Delhi – 110027 Weight-loss medications are prescription-only and require medical evaluation. This article is for education, not a substitute for a consultation.